|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benson AB, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: NCCN Guidelines insights: Colon cancer, version
2.2018. J Natl Compr Canc Netw. 16:359–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boland GM, Chang GJ, Haynes AB, Chiang YJ,
Chagpar R, Xing Y, Hu CY, Feig BW, You YN and Cormier JN:
Association between adherence to National Comprehensive Cancer
Network treatment guidelines and improved survival in patients with
colon cancer. Cancer. 119:1593–1601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Booth CM, Nanji S, Wei X, Peng Y, Biagi
JJ, Hanna TP, Krzyzanowska MK and Mackillop WJ: Use and
effectiveness of adjuvant chemotherapy for stage III colon cancer:
A population-based study. J Natl Compr Canc Netw. 14:47–56. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Casadaban L, Rauscher G, Aklilu M,
Villenes D, Freels S and Maker AV: Adjuvant chemotherapy is
associated with improved survival in patients with stage II colon
cancer. Cancer. 122:3277–3287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hines RB, Barrett A, Twumasi-Ankrah P,
Broccoli D, Engelman KK, Baranda J, Ablah EA, Jacobson L, Redmond
M, Tu W and Collins TC: Predictors of guideline treatment
nonadherence and the impact on survival in patients with colorectal
cancer. J Natl Compr Canc Netw. 13:51–60. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sargent DJ, Marsoni S, Monges G, Thibodeau
SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri
V, et al: Defective mismatch repair as a predictive marker for lack
of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim JE, Hong YS, Kim HJ, Kim KP, Lee JL,
Park SJ, Lim SB, Park IJ, Kim CW, Yoon YS, et al: Defective
mismatch repair status was not associated with DFS and OS in stage
II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol.
22 (Suppl 3):S630–S637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McCleary NJ, Meyerhardt JA, Green E,
Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ,
Saltz LB, Haller DG and Sargent DJ: Impact of age on the efficacy
of newer adjuvant therapies in patients with stage II/III colon
cancer: Findings from the ACCENT database. J Clin Oncol.
31:2600–2606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yothers G, O'Connell MJ, Allegra CJ,
Kuebler JP, Colangelo LH, Petrelli NJ and Wolmark N: Oxaliplatin as
adjuvant therapy for colon cancer: Updated results of NSABP C-07
trial, including survival and subset analyses. J Clin Oncol.
29:3768–3774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tournigand C, André T, Bonnetain F,
Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB,
Teixeira L and de Gramont A: Adjuvant therapy with fluorouracil and
oxaliplatin in stage II and elderly patients (between ages 70 and
75 years) with colon cancer: Subgroup analyses of the multicenter
international study of oxaliplatin, fluorouracil, and leucovorin in
the adjuvant treatment of colon cancer trial. J Clin Oncol.
30:3353–3360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI
|
|
13
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33 (Suppl 1):E102–E126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirashima M: Ecalectin/galectin-9, a novel
eosinophil chemoattractant: Its function and production. Int Arch
Allergy Immunol. 122 (Suppl 1):S6–S9. 2000. View Article : Google Scholar
|
|
16
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsushita N, Nishi N, Seki M, Matsumoto
R, Kuwabara I, Liu FT, Hata Y, Nakamura T and Hirashima M:
Requirement of divalent galactoside-binding activity of
ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem.
275:8355–8360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saita N, Goto E, Yamamoto T, Cho I,
Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H and
Hirashima M: Galectin-9 as a prognostic factor with antimetastatic
potential in breast cancer. Clin Cancer Res. 11:2962–2968. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamauchi A, Kontani K, Kihara M, Nishi N,
Yokomise H and Hirashima M: Galectin-9, a novel prognostic factor
with antimetastatic potential in breast cancer. Breast J. 12 (Suppl
2):S196–200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yasinska IM, Sakhnevych SS, Pavlova L, Teo
Hansen Selnø A, Teuscher Abeleira AM, Benlaouer O, Gonçalves Silva
I, Mosimann M, Varani L, Bardelli M, et al: The Tim-3-Galectin-9
pathway and its regulatory mechanisms in human breast cancer. Front
Immunol. 10:15942019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujita K, Iwama H, Sakamoto T, Okura R,
Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et
al: Galectin-9 suppresses the growth of hepatocellular carcinoma
via apoptosis in vitro and in vivo. Int J Oncol.
46:2419–2430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong F, Jin M, Cao D, Jia Z, Liu Y and
Jiang J: Galectin-3 not Galectin-9 as a candidate prognosis marker
for hepatocellular carcinoma. PeerJ. 8:e99492020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi K, Morishita A, Iwama H, Fujita
K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H,
et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation
by inducing apoptosis but not cell cycle arrest. Oncol Rep.
34:1761–1770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muthusami S, Ramachandran I,
Krishnamoorthy S, Sambandam Y, Ramalingam S, Queimado L, Chaudhuri
G and Ramachandran IK: Regulation of microRNAs in
inflammation-associated colorectal cancer: A mechanistic approach.
Endocr Metab Immune Disord Drug Targets. 21:67–76. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Masaki T, Tokuda M, Yoshida S, Nakai S,
Morishita A, Uchida N, Funaki T, Kita Y, Funakoshi F, Nonomura T,
et al: Comparison study of the expressions of myristoylated
alanine-rich C kinase substrate in hepatocellular carcinoma, liver
cirrhosis, chronic hepatitis, and normal liver. Int J Oncol.
26:661–671. 2005.PubMed/NCBI
|
|
30
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takano J, Morishita A, Fujihara S, Iwama
H, Kokado F, Fujikawa K, Fujita K, Chiyo T, Tadokoro T, Sakamoto T,
et al: Galectin-9 suppresses the proliferation of gastric cancer
cells in vitro. Oncol Rep. 35:851–860. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
D'Incalci M, Colombo T, Ubezio P,
Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R,
Sessa C, et al: The combination of yondelis and cisplatin is
synergistic against human tumor xenografts. Eur J Cancer.
39:1920–1926. 2003. View Article : Google Scholar
|
|
33
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, Regional, and National Cancer Incidence, Mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mishra J, Drummond J, Quazi SH, Karanki
SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer
treatments and scope for combinatorial approach to enhanced cancer
cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li C, Zuo D, Liu T, Yin L, Li C and Wang
L: Prognostic and clinicopathological significance of MUC family
members in colorectal cancer: A systematic review and
meta-analysis. Gastroenterol Res Pract. 2019:23916702019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nobumoto A, Nagahara K, Oomizu S, Katoh S,
Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A and Hirashima
M: Galectin-9 suppresses tumor metastasis by blocking adhesion to
endothelium and extracellular matrices. Glycobiology. 18:735–744.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Sun J, Ma C, Gao W, Song B, Xue H,
Chen W, Chen X, Zhang Y, Shao Q, et al: Reduced expression of
Galectin-9 contributes to a poor outcome in colon cancer by
inhibiting NK cell chemotaxis partially through the Rho/ROCK1
signaling pathway. PLoS One. 11:e01525992016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ahmed D, Eide PW, Eilertsen IA, Danielsen
SA, Eknæs M, Hektoen M, Lind GE and Lothe RA: Epigenetic and
genetic features of 24 colon cancer cell lines. Oncogenesis.
2:e712013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kramer G, Erdal H, Mertens HJ, Nap M,
Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using measurements of
different soluble forms of extracellular cytokeratin 18. Cancer
Res. 64:1751–1756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morishita A, Gong J and Masaki T:
Targeting receptor tyrosine kinases in gastric cancer. World J
Gastroenterol. 20:4536–4545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Morishita A, Gong J, Nomura T, Yoshida H,
Izuishi K, Suzuki Y, Kushida Y, Haba R, D'Armiento J and Masaki T:
The use of protein array to identify targetable receptor tyrosine
kinases for treatment of human colon cancer. Int J Oncol.
37:829–835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aubry A, Galiacy S and Allouche M:
Targeting ALK in cancer: Therapeutic potential of proapoptotic
peptides. Cancers (Basel). 11:2752019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Azizi R, Salemi Z, Fallahian F and Aghaei
M: Inhibition of didscoidin domain receptor 1 reduces
epithelial-mesenchymal transition and induce cell-cycle arrest and
apoptosis in prostate cancer cell lines. J Cell Physiol.
234:19539–19552. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nagano K, Yamashita T, Inoue M,
Higashisaka K, Yoshioka Y, Abe Y, Mukai Y, Kamada H, Tsutsumi Y and
Tsunoda S: Eph receptor A10 has a potential as a target for a
prostate cancer therapy. Biochem Biophys Res Commun. 450:545–549.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yamada S, Kato S, Matsuhisa T,
Makonkawkeyoon L, Yoshida M, Chakrabandhu T, Lertprasertsuk N,
Suttharat P, Chakrabandhu B, Nishiumi S, et al: Predominant mucosal
IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer.
World J Gastroenterol. 19:2941–2949. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH,
Song SK and Kim HS: Relationship between urokinase-type plasminogen
receptor, interleukin-8 gene expression and clinicopathological
features in gastric cancer. Oncology. 66:210–217. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee KE, Khoi PN, Xia Y, Park JS, Joo YE,
Kim KK, Choi SY and Jung YD: Helicobacter pylori and
interleukin-8 in gastric cancer. World J Gastroenterol.
19:8192–8202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sun Z, Meng C, Wang S, Zhou N, Guan M, Bai
C, Lu S, Han Q and Zhao RC: MicroRNA-1246 enhances migration and
invasion through CADM1 in hepatocellular carcinoma. BMC Cancer.
14:6162014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu X, Cao L, Zhang Y, Lian H, Sun Z and
Cui Y: MicroRNA-1246 inhibits cell invasion and epithelial
mesenchymal transition process by targeting CXCR4 in lung cancer
cells. Cancer Biomark. 21:251–260. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Du P, Lai YH, Yao DS, Chen JY and Ding N:
Downregulation of microRNA-1246 inhibits tumor growth and promotes
apoptosis of cervical cancer cells by targeting thrombospondin-2.
Oncol Lett. 18:2491–2499. 2019.PubMed/NCBI
|
|
52
|
Sun LN, Zhi Z, Chen LY, Zhou Q, Li XM, Gan
WJ, Chen S, Yang M, Liu Y, Shen T, et al: SIRT1 suppresses
colorectal cancer metastasis by transcriptional repression of
miR-15b-5p. Cancer Lett. 409:104–115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dong Y, Zhang N, Zhao S, Chen X, Li F and
Tao X: miR-221-3p and miR-15b-5p promote cell proliferation and
invasion by targeting Axin2 in liver cancer. Oncol Lett.
18:6491–6500. 2019.PubMed/NCBI
|
|
54
|
Tang T, Yang L, Cao Y, Wang M, Zhang S,
Gong Z, Xiong F, He Y, Zhou Y, Liao Q, et al: LncRNA AATBC
regulates Pinin to promote metastasis in nasopharyngeal carcinoma.
Mol Oncol. 14:2251–2270. 2020. View Article : Google Scholar : PubMed/NCBI
|
